Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation

Pulmonary Circulation

Volumn 6, Issue 2, 2016, Pages 191-195

  Talwar, Arunabh ^a,b   Sahni, Sonu ^a,b   Talwar, Ankoor ^c   Kohn, Nina ^b   Klinger, James R ^d  

^a Northwell Health   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UNION COLLEGE   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Access to health care; Disease severity; Pulmonary arterial hypertension; Pulmonary hypertension; Right heart catheterization; Socioeconomic status

Indexed keywords

EID: 84977523443     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/686489     Document Type: Article

References (27)

1. Millman M. Access to health care in America. Washington, DC: National Academies Press, 1993.
2. Syme SL, Berkman LF. Social class, susceptibility and sickness. Am J Epidemiol 1976; 104(1): 1-8.
3. Prescott E, Vestbo J. Socioeconomic status and chronic obstructive pulmonary disease. Thorax 1999; 54(8): 737-741.
4. Erzen D, Carriere KC, Dik N, Mustard C, Roos LL, Manfreda J, Anthonisen NR. Income level and asthma prevalence and care patterns. Am J Respir Crit Care Med 1997; 155(3): 1060-1065.
5. Schechter MS, Margolis PA. Relationship between socioeconomic status and disease severity in cystic fibrosis. J Pediatr 1998; 132(2): 260-264.
6. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiéry JL, Barbera JA, Beghetti M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34(6): 1219-1263.
7. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115(5): 343-349.
8. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 2010; 137(2): 376-387.
9. Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 1999; 341(18): 1359-1367.
10. Wu WH, Yang L, Peng FH, Yao J, Zou LL, Liu D, Jiang X, et al. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013; 187(3): 303-310.
11. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62(25 suppl.): D34-D41.
12. Geronimus AT, Bound J. Use of census-based aggregate variables to proxy for socioeconomic group: evidence from national samples. Am J Epidemiol 1998; 148(5): 475-486.
13. Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown, 1994.
14. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122(2): 164-172.
15. Olah ME, Gaisano G, Hwang SW. The effect of socioeconomic status on access to primary care: an audit study. CMAJ 2013; 185(6): E263-E269.
16. van Doorslaer E, Masseria C, Koolman X. Inequalities in access to medical care by income in developed countries. CMAJ 2006; 174(2): 177-183.
17. Schwartz KL, Crossley-May H, Vigneau FD, Brown K, Banerjee M. Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control 2003; 14(8): 761-766.
18. Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol 2009; 6(11): 712-722.
19. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336(2): 111-117.
20. Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371(9630): 2093-2100.
21. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106(12): 1477-1482.
22. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40(4): 780-788.
23. McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, Tan FK, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57(2): 318-326.
24. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, Powe NR. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002; 137(6): 479-486.
25. McLaughlin VV. Has the 6-min walk distance run its course? Chest 2012; 142(6): 1363-1364.
26. Bernheim SM, Ross JS, Krumholz HM, Bradley EH. Influence of patients’ socioeconomic status on clinical management decisions: a qualitative study. Ann Fam Med 2008; 6(1): 53-59.
27. Rabin DL, Richardson MS, Stein SR, Yeager H Jr. Sarcoidosis severity and socioeconomic status. Eur Respir J 2001; 18(3): 499-506.